RestorEar's 2024 Review

RestorEar's 2024 Review


As we jump into 2025, the RestorEar Team has been reflecting on our exciting past year. From conferences to events to clinical trial kick-offs, 2024 was a pivotal year for RestorEar and our work combating hearing loss. Here, we’d like to reflect on some amazing milestones, as well as a few things we are excited for in 2025.

Conferences, Events, and Outreach

The RestorEar Team attended a record number of events this year relating to hearing health. We participated in conferences, trade shows, and more, armed with both ReBound and ReBoundLite, and ready to spread awareness about cold therapy and hearing loss. We even debuted our products internationally after receiving an invite to BioJapan 2024 in Yokohama, Japan! Check out some outreach highlights below:

New Product Launch

In April, we launched ReBoundLite, our first product dedicated to cold comfort. Since then, we’ve shared ReBoundLite with hundreds of audiologists across the country for use in pain management and post-operative recovery for patients. Check out ReBoundLite here

Research and Publications

Members of the RestorEar team as well as our research collaborators have published countless articles in scientific journals in the last year. Here, we highlight a handful that our co-founders collaborated on:

Clinical Trials

2024 marked the launch of two separate clinical trials using RestorEar products. In the spring, RestorEar was awarded a Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH)/National Institute on Deafness and Other Communication Disorders (NIDCD) for our study titled “Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss”. The study began recruitment last month and will continue gathering data through 2025 on the efficacy of cold therapy for the prevention of noise-induced hearing loss in a group of occupationally at-risk firefighters.

A second study, titled “Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation”, also began recruiting this fall, with the first patients scheduled for operation at the start of 2025. 

Keep up to date with the studies on our Clinical Page and on clinicaltrials.gov

A Preview of 2025

While we are proud of these accomplishments in 2024, our work doesn’t stop here. Already, RestorEar has an exciting lineup of events and more for 2025. 

To kick off the year, we have been invited to attend the 50th RESI JPM Conference on January 14th in San Francisco, CA. We will also be attending the American Academy of Audiology HearTECH Expo 2025 in New Orleans, LA for the second year in a row. As the year progresses, we will continue to update our website and social media with more outreach appearances. 

On the research side, 2025 will be a huge year for clinical trials. As data continues to come in for both “Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss” and “Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation”, we will update clinicaltrials.gov. We also have multiple new trials in development, including some exciting work on tinnitus, so stay up to date on our website and by subscribing to our newsletter

To end, we’d like to thank you for your engagement in 2024 and continued support in 2025. We are excited to continue pushing the boundaries of hearing health technology in the new year. 

Happy New Year! 

- The RestorEar Team

Older Post Newer Post